CARE RATINGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,195 INR | -0.69% |
|
+10.06% | +25.63% |
| 03-19 | CARE Gets Board Nod for New Subsidiary in GIFT City, India | MT |
| 03-19 | CARE Ratings Limited Approves Incorporation of Wholly-Owned Subsidiary in GIFT City, Gujarat | CI |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 33.16 times its estimated earnings per share for the ongoing year.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Professional Information Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +25.63% | 431M | - | ||
| -5.12% | 68.39B | B+ | ||
| +0.45% | 3.87B | B+ | ||
| +11.13% | 277M | - | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CARERATING Stock
- Ratings CARE Ratings Limited
